TherapeuticsMD (TXMD) has submitted a New Drug Application (NDA) to the FDA seeking approval of Yuvvexy (vaginal estradiol) for the treatment of dyspareunia, moderate-to-severe vaginal pain during sexual intercourse, a symptom of vulvar and vaginal atrophy due to menopause.